ORIC

Oric Pharmaceuticals, Inc. ORIC

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Net income

$-41.49M

Quarter to Jun 30

Free cash flow

$-31.96M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$1.34B total
Nextech Invest, Ltd.
$77.57M0.0%
BlackRock, Inc.
$73.90M+14.0%
EcoR1 Capital, LLC
$72.87M0.0%
PRICE T ROWE ASSOCIATES INC /MD/
$71.67M+22.8%
VIKING GLOBAL INVESTORS LP
$55.52M-12.0%
STATE STREET CORP
$53.00M+32.2%
SR ONE CAPITAL MANAGEMENT, LP
$49.98M+2.2%
VR Adviser, LLC
$46.78M0.0%
NEA Management Company, LLC
$44.60M0.0%
VANGUARD CAPITAL MANAGEMENT LLC
$42.79M+7.2%
AIHC Capital Management Ltd
$41.46M+55.7%
ALKEON CAPITAL MANAGEMENT LLC
$40.49M-17.0%
Column Group LLC
$38.35M0.0%
Siren, L.L.C.
$32.47M0.0%
FMR LLC
$28.54M+8.3%
CITADEL ADVISORS LLC
$28.11M+7.1%
GOLDMAN SACHS GROUP INC
$26.55M+66.1%
GEODE CAPITAL MANAGEMENT, LLC
$22.64M+13.7%
First Turn Management, LLC
$21.85M0.0%
ORBIMED ADVISORS LLC
$21.82M-25.2%
Integral Health Asset Management, LLC
$20.58M+35.7%
MPM BioImpact LLC
$20.38M+4.3%
Vivo Capital, LLC
$20.02M0.0%
DIMENSIONAL FUND ADVISORS LP
$19.50M+22.4%
FRANKLIN RESOURCES INC
$19.47M+23.7%
See all 181 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Loading ratio trend…

About Oric Pharmaceuticals, Inc. (ORIC): stock profile, AI score and financials

Oric Pharmaceuticals, Inc. (ORIC) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. ORIC is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), Oric Pharmaceuticals, Inc. reports net income of $-41.5M, free cash flow of $-32.0M. ORIC trades on the Nasdaq exchange and files with the SEC under CIK 1796280. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ORIC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Oric Pharmaceuticals, Inc. directly from SEC EDGAR.

SEC EDGAR: CIK 1796280 →